Citius Oncology signs distribution agreement for Lymphir in Southern Europe

Citius Oncology (CTOR)is engaging with regional distribution partners to make Lymphir available to eligible patients through country-specific Named Patient Programs – NPPs – in Europe, South America and the Middle East. As part of its NPP strategy, Citius has entered into an exclusive distribution agreement with Integris Pharma, headquartered in Athens, Greece. The partnership covers Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia. Named Patient Programs are formally recognized pathways designed to give patients earlier access to promising new medicines in advance of full marketing authorization and commercial availability in markets outside the U.S. Under these programs, a treating physician may request a therapy on behalf of an individual patient when no adequate approved alternatives exist. These programs provide access, where permitted by local law, and do not constitute commercial approval of Lymphir outside the U.S. Integris Pharma is a privately-owned specialty pharmaceutical company in Greece and Southern Europe. Citius is in active discussions with multiple prospective distribution partners across several European Union member states, in South America, and in select Middle Eastern territories.